An Atlas of Variant Effects to understand the genome at nucleotide resolution
- PMID: 37394429
- PMCID: PMC10316620
- DOI: 10.1186/s13059-023-02986-x
An Atlas of Variant Effects to understand the genome at nucleotide resolution
Abstract
Sequencing has revealed hundreds of millions of human genetic variants, and continued efforts will only add to this variant avalanche. Insufficient information exists to interpret the effects of most variants, limiting opportunities for precision medicine and comprehension of genome function. A solution lies in experimental assessment of the functional effect of variants, which can reveal their biological and clinical impact. However, variant effect assays have generally been undertaken reactively for individual variants only after and, in most cases long after, their first observation. Now, multiplexed assays of variant effect can characterise massive numbers of variants simultaneously, yielding variant effect maps that reveal the function of every possible single nucleotide change in a gene or regulatory element. Generating maps for every protein encoding gene and regulatory element in the human genome would create an 'Atlas' of variant effect maps and transform our understanding of genetics and usher in a new era of nucleotide-resolution functional knowledge of the genome. An Atlas would reveal the fundamental biology of the human genome, inform human evolution, empower the development and use of therapeutics and maximize the utility of genomics for diagnosing and treating disease. The Atlas of Variant Effects Alliance is an international collaborative group comprising hundreds of researchers, technologists and clinicians dedicated to realising an Atlas of Variant Effects to help deliver on the promise of genomics.
Keywords: Functional genomics; Genome interpretation; Global alliance; Multiplexed assay of variant effect; Saturation mutagenesis; Variant effect.
© 2023. The Author(s).
Conflict of interest statement
A.L.G. declares that her spouse is an employee of Genentech and holds stock options in Roche. D.J.A. is a consultant for Microbiotica and Astra Zeneca. D.S.M. is a consultant for Insitro, Dyno and Octant. J.T.N. receives research support from Bristol Myers Squibb. F.P.R. holds shares in Ranomics, Inc., and is an investor and advisor for SeqWell, Inc. and Constantiam Biosciences, Inc. L.M.S. is a consultant for Nostos Genomics. W.C.H. is a consultant for Thermo Fisher, Solasta Ventures, MPM Capital, Tyra Biosciences, Frontier Medicines, Jubilant Therapeutics, KSQ Therapeutics, RAPPTA Therapeutics, Serinus Biosciences, Hexagon Bio, Function Oncolog, Riva Therapeutics, and Calyx. M.E.H. is a consultant for AstraZeneca and co-founder, director, shareholder of Congenica Ltd.
Figures



References
Publication types
MeSH terms
Grants and funding
- MR/V000292/1/MRC_/Medical Research Council/United Kingdom
- R01 CA260415/CA/NCI NIH HHS/United States
- U01 CA242954/CA/NCI NIH HHS/United States
- R01 HL164675/HL/NHLBI NIH HHS/United States
- WT_/Wellcome Trust/United Kingdom
- R01 HL152066/HL/NHLBI NIH HHS/United States
- UM1 DK126185/DK/NIDDK NIH HHS/United States
- CRUK_/Cancer Research UK/United Kingdom
- 200837/Z/16/Z/WT_/Wellcome Trust/United Kingdom
- RM1 HG010461/HG/NHGRI NIH HHS/United States
- DP2 GM146252/GM/NIGMS NIH HHS/United States
- UM1 HG011989/HG/NHGRI NIH HHS/United States
- U01 CA176058/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources